Avastin Injection (Bevacizumab): The Standard in Anti-Angiogenic Cancer Therapy – Global Supply by Ernest Oncology
In the oncology landscape of 2026, Avastin (active ingredient Bevacizumab) remains one of the most versatile and critical biological agents in clinical use. As a recombinant humanized monoclonal antibody, Avastin has revolutionized the treatment of multiple solid tumors by targeting the vascular endothelial growth factor (VEGF), effectively "starving" tumors of the blood supply they need to grow and spread.
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Avastin to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain management and rapid global delivery.
Technical Product Profile: Avastin (Bevacizumab)
Avastin is a solution for intravenous (IV) infusion that selectively binds to and neutralizes the biologic activity of human VEGF.
Product Specifications
Active Ingredient: Bevacizumab
Common Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials
Pharmacological Class: Antineoplastic Agent; Monoclonal Antibody; VEGF Inhibitor
Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze or shake.
Primary Clinical Indications
Metastatic Colorectal Cancer (mCRC): Used as a first-line or second-line treatment in combination with fluoropyrimidine-based chemotherapy.
Non-Small Cell Lung Cancer (NSCLC): First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC.
Glioblastoma: For the treatment of recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon alfa.
Cervical and Ovarian Cancers: Effective in persistent, recurrent, or metastatic cases in combination with specific chemotherapy regimens.
Mechanism of Action: Inhibiting Tumor Angiogenesis
Avastin works through a unique process called anti-angiogenesis.
VEGF Neutralization: Avastin binds to VEGF, a protein that stimulates the growth of new blood vessels.
Vascular Regression: By blocking VEGF, Avastin causes the regression of existing tumor microvasculature.
Inhibition of New Growth: It prevents the formation of new blood vessels (angiogenesis), which is essential for tumor growth beyond a few millimeters.
Enhanced Chemotherapy Delivery: By normalizing tumor vascular permeability, it can improve the delivery of co-administered chemotherapeutic agents to the tumor core.
Global Export Excellence: UK, USA, UAE, Australia, & South Africa
Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring that oncology providers have consistent access to high-quality biological medications.
United Kingdom & London: We serve NHS trusts and private oncology centers in London, adhering to all MHRA biological import and safety standards.
United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced cancer care.
Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping.
Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological frameworks.
South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
